NO20070295L - Nye CIS-imidazoliner - Google Patents

Nye CIS-imidazoliner

Info

Publication number
NO20070295L
NO20070295L NO20070295A NO20070295A NO20070295L NO 20070295 L NO20070295 L NO 20070295L NO 20070295 A NO20070295 A NO 20070295A NO 20070295 A NO20070295 A NO 20070295A NO 20070295 L NO20070295 L NO 20070295L
Authority
NO
Norway
Prior art keywords
imidazolines
compounds
new cis
cis
new
Prior art date
Application number
NO20070295A
Other languages
English (en)
Norwegian (no)
Inventor
Norman Kong
Binh Thanh Vu
Gregory Jay Haley
Emily Aijun Liu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34969621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070295(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20070295L publication Critical patent/NO20070295L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20070295A 2004-06-17 2007-01-16 Nye CIS-imidazoliner NO20070295L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58044104P 2004-06-17 2004-06-17
US67419605P 2005-04-22 2005-04-22
PCT/EP2005/006167 WO2005123691A1 (en) 2004-06-17 2005-06-08 Novel cis-imidazolines

Publications (1)

Publication Number Publication Date
NO20070295L true NO20070295L (no) 2007-01-17

Family

ID=34969621

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070295A NO20070295L (no) 2004-06-17 2007-01-16 Nye CIS-imidazoliner

Country Status (16)

Country Link
US (1) US7893278B2 (ru)
EP (1) EP1758868A1 (ru)
JP (1) JP4809336B2 (ru)
KR (1) KR100855929B1 (ru)
AR (1) AR049647A1 (ru)
AU (1) AU2005254643A1 (ru)
BR (1) BRPI0512237A (ru)
CA (1) CA2569598A1 (ru)
IL (1) IL179730A0 (ru)
MX (1) MXPA06014806A (ru)
NO (1) NO20070295L (ru)
NZ (1) NZ551659A (ru)
RU (1) RU2408593C2 (ru)
SG (1) SG148177A1 (ru)
TW (1) TW200637828A (ru)
WO (1) WO2005123691A1 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579368B2 (en) * 2005-03-16 2009-08-25 Hoffman-La Roche Inc. Cis-imidazolines
ES2538714T3 (es) 2005-12-01 2015-06-23 F. Hoffmann-La Roche Ag Derivados de 2,4,5-trifenil-imidazolina como inhibidores de la interacción entre las proteínas p53 y MDM2 para el uso en calidad de agentes anticancerosos
WO2007082805A1 (en) * 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
BRPI0720546A2 (pt) 2006-12-14 2015-06-23 Daiichi Sankyo Co Ltd Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
CA2939778C (en) * 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
US7625895B2 (en) * 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
EP2152787B1 (en) * 2007-05-21 2011-11-16 Dow Global Technologies LLC Coated object
CN101983057A (zh) * 2008-01-30 2011-03-02 新加坡科技研究局 用咪唑和咪唑啉化合物治疗纤维变性和癌症的方法
EP2803356A1 (en) * 2008-03-31 2014-11-19 Agency for Science, Technology and Research Method for treating neurological disorders with imidazolium and imidazolinium compounds
WO2009151069A1 (ja) 2008-06-12 2009-12-17 第一三共株式会社 ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
ES2463820T3 (es) 2009-01-16 2014-05-29 Daiichi Sankyo Company, Limited Derivado de imidazotiazol que tiene estructura de anillo de prolina
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US8889863B2 (en) 2010-07-16 2014-11-18 Vanderbilt University Stereoselective methods, catalysts and intermediates for the synthesis of (−)-Nutlin-3 and related compounds
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
US9266860B2 (en) 2010-09-30 2016-02-23 St. Jude Children's Research Hospital Aryl-substituted imidazoles
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
AU2014236812B2 (en) 2013-03-14 2018-03-01 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
PT2970383T (pt) 2013-03-15 2021-06-03 Univ Texas Processo de tratamento de fibrose
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
CA3100140C (en) 2014-01-28 2023-10-24 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
WO2017157813A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for the treatment of hematological malignancies
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
AU2017418538B2 (en) 2017-06-16 2021-10-21 Unity Biotechnology, Inc. Synthesis method for producing enantiomerically pure cis-imidazoline compounds for pharmaceutical use
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye
JP7204391B2 (ja) * 2018-09-18 2023-01-16 株式会社東芝 酸性ガス吸収剤、酸性ガスの除去方法及び酸性ガス除去装置
KR102622992B1 (ko) * 2021-03-29 2024-01-10 주식회사 퓨전바이오텍 이미다졸린 유도체 및 이의 중간체 제조방법
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2441498A (en) * 1943-07-15 1948-05-11 Astra Apotekarnes Kem Fab Alkyl glycinanilides
JPH02101065A (ja) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
DE4203547A1 (de) 1992-02-07 1993-08-12 Knoll Ag Verfahren zur racemattrennung von verapamil
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
US6653501B2 (en) 2001-06-27 2003-11-25 Napro Biotherapeutics, Inc. Chiral resolution method for producing compounds useful in the synthesis of taxanes
DE60225719T2 (de) * 2001-12-18 2009-04-23 F. Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
CA2468783A1 (en) * 2001-12-18 2003-06-26 F. Hoffmann-La Roche Ag Cis-imidazolines as mdm2 inhibitors
ATE414693T1 (de) 2004-05-18 2008-12-15 Hoffmann La Roche Neuartige cis-imidazoline

Also Published As

Publication number Publication date
CA2569598A1 (en) 2005-12-29
KR100855929B1 (ko) 2008-09-02
AR049647A1 (es) 2006-08-23
RU2007101275A (ru) 2008-07-27
KR20070027590A (ko) 2007-03-09
JP4809336B2 (ja) 2011-11-09
US7893278B2 (en) 2011-02-22
WO2005123691A1 (en) 2005-12-29
TW200637828A (en) 2006-11-01
MXPA06014806A (es) 2007-02-12
SG148177A1 (en) 2008-12-31
EP1758868A1 (en) 2007-03-07
RU2408593C2 (ru) 2011-01-10
IL179730A0 (en) 2007-05-15
BRPI0512237A (pt) 2008-02-19
AU2005254643A1 (en) 2005-12-29
NZ551659A (en) 2010-08-27
US20050282803A1 (en) 2005-12-22
JP2008502620A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
NO20070295L (no) Nye CIS-imidazoliner
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes
NO20054852L (no) GFAT inhibitorer
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
MY144588A (en) Novel coumarin derivative having antitumor activity
NO20092033L (no) Nye forbindelser
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
HK1091121A1 (en) Substituted 2-aminotetralins for the treatment of depressions
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20074703L (no) Antibakterielle piperidinderivater
NO20082388L (no) Heteroaryl substituerte piperidinderivater som L-CPT1 inhibitorer
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
RS101304A (sr) Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
NO20074872L (no) Pyrazoler
NO20082496L (no) Pyrazinderivater
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
NO20060114L (no) Naftylenderivater som cytokrom P450-inhibitorer
NO20071658L (no) Alkil-pyridiner som 11-beta-inhibitorer for diabetes
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application